BioCentury
ARTICLE | Strategy

Getting real at TB alliance

September 8, 2008 7:00 AM UTC

The not-for-profit world may focus on diseases ignored by the corporate world, but the problem is that they rarely actually get any drugs through development. The reasons cited by successful drug developers include lack of understanding of what kind of molecules can become successful drugs; lack of understanding of IP, manufacturing and clinical design issues; and the absence of the kinds of corporate pressures that lead companies to kill programs that won't work.

Applying strict criteria in the absence of corporate pressures became the job of Jerome Premmereur when he took over as president and CEO of the Global Alliance for TB Drug Development (TBA) in March...